CC
AGIO icon

Columbia Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Columbia Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$591K Buy
+5,266
New +$470K 0.65% 73

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Columbia Capital's AGIO Position: Q4 2014 in Review

Columbia Capital opened a new position in Agios Pharmaceuticals (AGIO) in Q4 2014: 5,266 shares worth $591K. The stake represents 0.65% of the portfolio and ranks #73 among its holdings.

142 funds tracked by Wall St. Rank hold AGIO as of Q4 2014.

  • Columbia Capital held 5,266 shares of Agios Pharmaceuticals worth $591K as of Q4 2014.
  • Agios Pharmaceuticals was a new Columbia Capital position in Q4 2014.
  • Agios Pharmaceuticals made up 0.65% of Columbia Capital's portfolio in Q4 2014, its #73 holding.
  • 142 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2014.

Based on Columbia Capital's 13F filing for Q4 2014, filed 11 Feb 2015.